Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Neurology and Neuroscience Reports
Erschienen in: Current Neurology and Neuroscience Reports 7/2015

01.07.2015 | Behavior (HS Kirshner, Section Editor)

Psychotic Symptoms in Frontotemporal Dementia

verfasst von: Devin Hall, Elizabeth C. Finger

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Although psychotic features have long been recognized in association with frontotemporal dementia (FTD), recent genetic discoveries enabling further subtyping of FTD have revealed that psychotic symptoms are frequent in some forms of FTD. Hallucinations and delusions can even precede onset of other cognitive or behavioural symptoms in patients with FTD. In this review, we explore the frequency and types of psychotic symptoms reported in patients with FTD, as well as in other neuropsychiatric disorders, to aid practitioners’ consideration of these features in the diagnosis of FTD and related disorders.
Literatur
1.
Gustafson L, Risberg J. Delusions and hallucinations in old age. In: Katona C, Lewy R, editors. Delusions and hallucinations in old age. London: Gaskell; 1992. p. 218–29.
2.
Lillo P et al. Neurobehavioral features in frontotemporal dementia with amyotrophic lateral sclerosis. Arch Neurol. 2010;67(7):826–30.CrossRefPubMed
3.•
Sha SJ et al. Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features. Neurology. 2012;79(10):1002–11. This is one of the seminal papers describing the most common presenting symptoms, including psychosis, in a cohort of patients with FTD and C9ORF72 mutations.CrossRefPubMedCentralPubMed
4.
5.•
Snowden JS et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain. 2012;135(Pt 3):693–708. This report describes a large cohort of patients with FTD and provides excellent detailed descriptions of psychotic symptoms in FTD patients with and without C9ORF72 mutations.CrossRefPubMedCentralPubMed
6.
Schoder D et al. Morbid risk for schizophrenia in first-degree relatives of people with frontotemporal dementia. Br J Psychiatry. 2010;197(1):28–35.CrossRefPubMed
7.•
Landqvist Waldo M et al. Psychotic symptoms in frontotemporal dementia: a diagnostic dilemma? Int Psychogeriatr. 2015;27(4):531–9. This is one of the largest autopsy-confirmed studies to date to examine correlations between the presence and type of psychotic symptoms and patterns of atrophy in 97 consecutive patients with confirmed FTLD. CrossRefPubMedCentralPubMed
8.
9.
Le Ber I et al. Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain. 2008;131(Pt 3):732–46.CrossRefPubMed
10.
Bathgate D et al. Behaviour in frontotemporal dementia, Alzheimer’s disease and vascular dementia. Acta Neurol Scand. 2001;103(6):367–78.CrossRefPubMed
11.
Kertesz A et al. Psychosis and hallucinations in frontotemporal dementia with the C9ORF72 mutation: a detailed clinical cohort. Cogn Behav Neurol. 2013;26(3):146–54.CrossRefPubMedCentralPubMed
12.
Harciarek M, Kertesz A. The prevalence of misidentification syndromes in neurodegenerative diseases. Alzheimer Dis Assoc Disord. 2008;22(2):163–9.
13.
Leger GC, Banks SJ. Neuropsychiatric symptom profile differs based on pathology in patients with clinically diagnosed behavioral variant frontotemporal dementia. Dement Geriatr Cogn Disord. 2014;37(1-2):104–12.CrossRefPubMedCentralPubMed
14.
15.
Mahoney CJ et al. Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions. Alzheimers Res Ther. 2012;4(5):41.CrossRefPubMedCentralPubMed
16.
Hsiung GY et al. Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. Brain. 2012;135(Pt 3):709–22.CrossRefPubMedCentralPubMed
17.
Dobson-Stone C et al. C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. Neurology. 2012;79(10):995–1001.CrossRefPubMedCentralPubMed
18.
19.
Le Ber I. Genetics of frontotemporal lobar degeneration: an up-date and diagnosis algorithm. Rev Neurol (Paris). 2013;169(10):811–9.CrossRef
20.
Boeve BF et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain. 2012;135(Pt 3):765–83.CrossRefPubMedCentralPubMed
21.
Cruts M, Kumar-Singh S, Van Broeckhoven C. Progranulin mutations in ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Curr Alzheimer Res. 2006;3(5):485–91.CrossRefPubMed
22.
Chen-Plotkin AS et al. Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. Arch Neurol. 2011;68(4):488–97.CrossRefPubMedCentralPubMed
23.
Le Ber I et al. Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat. 2007;28(9):846–55.CrossRefPubMed
24.
Seelaar H et al. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry. 2011;82(5):476–86.CrossRefPubMed
25.
Rademakers R, Neumann M, Mackenzie IR. Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol. 2012;8(8):423–34.PubMedCentralPubMed
26.
Khan BK et al. Schizophrenia or neurodegenerative disease prodrome? Outcome of a first psychotic episode in a 35-year-old woman. Psychosomatics. 2012;53(3):280–4.CrossRefPubMedCentralPubMed
27.
Velakoulis D et al. Frontotemporal dementia presenting as schizophrenia-like psychosis in young people: clinicopathological series and review of cases. Br J Psychiatry. 2009;194(4):298–305.CrossRefPubMed
28.
Mendez MF et al. Psychotic symptoms in frontotemporal dementia: prevalence and review. Dement Geriatr Cogn Disord. 2008;25(3):206–11.CrossRefPubMed
29.
Passant U et al. Psychiatric symptoms and their psychosocial consequences in frontotemporal dementia. Alzheimer Dis Assoc Disord. 2005;19 Suppl 1:S15–8.CrossRefPubMed
30.
Harciarek M et al. Schizophrenia and frontotemporal dementia: shared causation? Int Rev Psychiatry. 2013;25(2):168–77.CrossRefPubMed
31.
Pose M et al. The overlap of symptomatic dimensions between frontotemporal dementia and several psychiatric disorders that appear in late adulthood. Int Rev Psychiatry. 2013;25(2):159–67.CrossRefPubMed
32.
Momeni P et al. Familial early onset frontotemporal dementia caused by a novel S356T MAPT mutation, initially diagnosed as schizophrenia. Clin Neurol Neurosurg. 2010;112(10):917–20.CrossRefPubMed
33.
34.
Yoshino, Y., et al., No abnormal hexanucleotide repeat expansion of C9ORF72 in Japanese schizophrenia patients. J Neural Transm, 2014.
35.
Huey ED et al. C9ORF72 repeat expansions not detected in a group of patients with schizophrenia. Neurobiol Aging. 2013;34(4):1309 e9–10.CrossRef
36.
Galimberti D et al. C9ORF72 hexanucleotide repeat expansion is a rare cause of schizophrenia. Neurobiol Aging. 2014;35(5):1214.e7–10.CrossRef
37.
Cooper JJ, Ovsiew F. The relationship between schizophrenia and frontotemporal dementia. J Geriatr Psychiatry Neurol. 2013;26(3):131–7.CrossRefPubMed
38.
Harris MJ, Jeste DV. Late-onset schizophrenia: an overview. Schizophr Bull. 1988;14(1):39–55.CrossRefPubMed
39.
40.
Snowden JS et al. Psychosis, C9ORF72 and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2012;83(10):1031–2.CrossRefPubMed
41.
McKeith I. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis. 2006;9(3 Suppl):417–23.PubMed
42.
Engelborghs S et al. Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study. Int J Geriatr Psychiatry. 2005;20(11):1028–37.CrossRefPubMed
43.
Craig D et al. A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer’s disease. Am J Geriatr Psychiatr. 2005;13(6):460–8.CrossRef
44.
Paulsen JS et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000;54(10):1965–71.CrossRefPubMed
45.
Tariot PN et al. The behavior rating scale for dementia of the consortium to establish a registry for Alzheimer’s disease. The behavioral pathology committee of the consortium to establish a registry for Alzheimer’s disease. Am J Psychiatry. 1995;152(9):1349–57.CrossRefPubMed
46.
Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer’s disease. I: disorders of thought content. Br J Psychiatry. 1990;157:72–6.
47.
Mendez MF et al. False reports from patients with frontotemporal dementia: delusions or confabulations? Behav Neurol. 2011;24(3):237–44.CrossRefPubMed
48.
Chan D et al. The clinical profile of right temporal lobe atrophy. Brain. 2009;132(Pt 5):1287–98.CrossRefPubMed
49.
Bruen PD et al. Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer’s disease. Brain. 2008;131(Pt 9):2455–63.CrossRefPubMed
50.
Whitehead D et al. Frontotemporal atrophy associated with paranoid delusions in women with Alzheimer’s disease. Int Psychogeriatr. 2012;24(1):99–107.CrossRefPubMed
51.
Serra L et al. Are the behavioral symptoms of Alzheimer’s disease directly associated with neurodegeneration? J Alzheimers Dis. 2010;21(2):627–39.PubMed
52.
Ismail Z et al. Neuroimaging of delusions in Alzheimer’s disease. Psychiatry Res. 2012;202(2):89–95.CrossRefPubMed
53.
54.
Gramaglia C et al. Early onset frontotemporal dementia with psychiatric presentation due to the C9ORF72 hexanucleotide repeat expansion: a case report. BMC Neurol. 2014;14(1):228.CrossRefPubMedCentralPubMed
55.
Kobayashi T et al. Effectiveness of electroconvulsive therapy for depression and Cotard’s syndrome in a patient with frontotemporal lobe dementia. Case Rep Psychiatry. 2012;2012:627460.PubMedCentralPubMed
56.
Pijnenburg YA et al. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int J Geriatr Psychiatry. 2003;18(1):67–72.CrossRefPubMed
57.
Arighi A et al. Early onset behavioral variant frontotemporal dementia due to the C9ORF72 hexanucleotide repeat expansion: psychiatric clinical presentations. J Alzheimers Dis. 2012;31(2):447–52.PubMed
58.
Loy CT et al. The case of a 48 year-old woman with bizarre and complex delusions. Nat Rev Neurol. 2010;6(3):175–9.CrossRefPubMed
59.
Arosio B et al. GRN Thr272fs clinical heterogeneity: a case with atypical late onset presenting with a dementia with Lewy bodies phenotype. J Alzheimers Dis. 2013;35(4):669–74.
60.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders fifth edition. Washington, DC: American Psychiatric Publishing; 2013.
61.
Caliyurt O et al. Cotard’s syndrome with schizophreniform disorder can be successfully treated with electroconvulsive therapy: case report. J Psychiatry Neurosci. 2014;29(2):138–41.
62.
Debruyne H et al. Cotard’s syndrome: a review. Curr Psychiatry Rep. 2009;11(3):197–202.
63.
Langdon R et al. The Fregoli delusion: a disorder of person identification and tracking. Top Cogn Sci. 2014;6(4):615–31.
64.
Simon-Sanchez J et al. The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain. 2012;135(Pt 3):723–35.
65.
Tartaglia MC et al. Delusions and hallucinations in frontotemporal dementia: a clinicopathologic case report. Cogn Behav Neurol. 2008;21(2):107–10.
Metadaten
Titel
Psychotic Symptoms in Frontotemporal Dementia
verfasst von
Devin Hall
Elizabeth C. Finger
Publikationsdatum
01.07.2015
Verlag
Springer US
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 7/2015
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-015-0567-8

Weitere Artikel der Ausgabe 7/2015

Current Neurology and Neuroscience Reports 7/2015 Zur Ausgabe

Neuroimaging (DJ Brooks, Section Editor)

Developments in the Role of Transcranial Sonography for the Differential Diagnosis of Parkinsonism

Genetics (V Bonifati, Section Editor)

LRRK2 Pathways Leading to Neurodegeneration

Neuroimaging (DJ Brooks, Section Editor)

The Relationship Between Atrophy and Hypometabolism: Is It Regionally Dependent in Dementias?

Neurology of Systemic Diseases (J Biller, Section Editor)

The Neurology of Solid Organ Transplantation

Neuro-Ophthalmology (A Kawasaki, Section Editor)

Retinal Vascular Changes are a Marker for Cerebral Vascular Diseases

Pediatric Neurology (P Pearl, Section Editor)

The Genetics of the Epilepsies

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise